Skip to content

Cytek Biosciences, Inc. CTKB Provision for Credit Losses

Provision for Credit Losses at other companies

Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$1.19M-42.7%
HTF
Heartflow, Inc. Common StockHTFL
$359K+247%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s provision for credit losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s provision for credit losses?
Cytek Biosciences, Inc. (CTKB) reported provision for credit losses of $459K in Q1 2026.
What does provision for credit losses mean?
Non-cash provision for expected loan losses, added back in operating cash flow since it's a reserve build, not a cash payment.